Content about Specialty pharmacy

December 17, 2013

Grocer A&P, which operates more than 300 stores across six states, has signed a three-year agreement with Innovatix, whereby it will serve as A&P’s exclusive provider of specialty pharmacy services.

NEW YORK  — Grocer A&P, which operates more than 300 stores across six states, has signed a three-year agreement with Innovatix, whereby it will serve as A&P’s exclusive provider of specialty pharmacy services.

December 17, 2013

Three organizations will receive part of $1.3 million in funding that German drug maker Merck KGaA and the National Multiple Sclerosis Society are distributing for MS research.

NEW YORK — Three organizations will receive part of $1.3 million in funding that German drug maker Merck KGaA and the National Multiple Sclerosis Society are distributing for MS research.

EMD Serono, the name the Merck KGaA uses in the United States to avoid confusion with U.S.-based Merck & Co., and the National MS Society said the money will help encourage early-stage drug discovery for the autoimmune disease.

December 17, 2013

Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.

December 17, 2013

Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

BURLINGTON, Mass. — Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

December 16, 2013

A redesigned version of an injector pen used to treat infertility is available for distribution in the United States, the manufacturer said.

ROCKLAND, Mass. — A redesigned version of an injector pen used to treat infertility is available for distribution in the United States, the manufacturer said Monday.

EMD Serono, a subsidiary of German drug maker Merck KGaA, said that Gonal-f RFF Redi-ject, a disposable, pre-filled pen used for the drug Gonal-f RFF (follitropin alfa), had become available. The Food and Drug Administration approved the redesigned pen in October. Merck KGaA operates in the United States under the name EMD in order to avoid confusion with U.S.-based Merck & Co.

December 16, 2013

A drug made by Novartis extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.

BASEL, Switzerland — A drug marketed by Novartis and Incyte Corp. extends the lives of patients with a life-threatening blood cancer to a greater extent than conventional therapy or placebo, according to results of a late-stage clinical trial.

Novartis announced the results of two phase-3 studies of Jakavi (ruxolitinib) in patients with myelofibrosis, presenting them at the American Society of Hematology's annual meeting and exposition in New Orleans.

December 13, 2013

The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

ALLEGAN, Mich. — The Irish High Court has approved Perrigo's pending acquisition of Irish drug maker Elan, the companies said Friday.

December 13, 2013

Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

NEW YORK — Pharmacy benefit manager Express Scripts hopes to drive down the cost of new drugs to treat hepatitis C by pitting their manufacturers against each other, according to published reports.

Bloomberg News reported that ESI would pit companies like Gilead Sciences against others such as AbbVie when the new treatments become available in 2014 or 2015. The Food and Drug Administration announced last week the approval of Gilead's new drug, Sovaldi (sofosbuvir), which is designed to cut by three quarters the time needed for treatment.

December 12, 2013

A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.

PRINCETON, N.J. — A panel of experts at the Food and Drug Administration has recommended approval for an experimental biotech drug under development by Bristol-Myers Squibb and AstraZeneca for a group of rare metabolic disorders.

December 12, 2013

Drug maker Shire has launched an online information website for patients in the United States with ulcerative colitis, the company said.

CHESTERBROOK, Pa. — Drug maker Shire has launched an online information website for patients in the United States with ulcerative colitis, the company said Thursday.

The website, Shire UCentral, includes information for patients and caregivers. UC is a chronic disease that causes inflammation in the lining of the colon and rectum.

December 11, 2013

While the Patient Protection and Affordable Care Act will undoubtedly reshape the U.S. healthcare industry for years to come, it is only one of many factors that will emerge next year, according to a new report.

NEW YORK — While the Patient Protection and Affordable Care Act will undoubtedly reshape the U.S. healthcare industry for years to come, it is only one of many factors that will emerge next year, according to a new report released Wednesday.

The report, Top Health Industry Issues for 2014, by PwC's Health Research Institute, was based on a survey of 1,000 consumers and interviews with health industry leaders.

December 11, 2013

McKesson Pharmacy Systems and Automation introduced a new EnterpriseRx Flexible Delivery solution that expands the reach of outpatient and retail pharmacies beyond their local communities.

PITTSBURGH — McKesson Pharmacy Systems and Automation on Wednesday introduced a new EnterpriseRx Flexible Delivery solution that expands the reach of outpatient and retail pharmacies beyond their local communities. The new solution can be seen at the American Society of Health-System Pharmacists Midyear Clinical Meeting, which runs Dec. 8 to12.

December 10, 2013

Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

NORTH CHICAGO, Ill. — Nearly all patients taking an experimental treatment for hepatitis C developed by AbbVie were cured, the drug maker said Tuesday.

December 10, 2013

An expert panel at the Food and Drug Administration has given a thumbs-up to an experimental drug made by Takeda Pharmaceutical Co. for treating ulcerative colitis and Crohn's disease, the drug maker said.

DEERFIELD, Ill. — An expert panel at the Food and Drug Administration has given a thumbs-up to an experimental drug made by Takeda Pharmaceutical Co. for treating ulcerative colitis and Crohn's disease, the drug maker said.

December 10, 2013

Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.

JERUSALEM — Teva Pharmaceutical Industries anticipates that it could lose about $500 million in sales next year if a generic version of its multiple sclerosis drug hits the market, the Israeli drug maker said Tuesday.

December 9, 2013

Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

PITTSBURGH — Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

December 9, 2013

Institutional pharmacy PharMerica Corp. has acquired a minority stake in specialty pharmacy company Onco360, the two companies said Monday.

NEW YORK — Institutional pharmacy PharMerica Corp. has acquired a minority stake in specialty pharmacy company Onco360, the two companies said Monday.

Onco360, which focuses on oncology services, and PharMerica called the stake "significant," and PharMerica will have the option to acquire the rest of the company over the next several years, but financial terms of the deal were not disclosed. Onco360 currently has sales of more than $100 million per year.

December 9, 2013

Two patients in Boston whom researchers had thought were cured of HIV have experienced a relapse of the infection, according to published reports.

NEW YORK — Two patients in Boston whom researchers had thought were cured of HIV have experienced a relapse of the infection, according to published reports.

The New York Daily News reported that the two men, who were believed cured after receiving bone marrow transplants for lymphoma, had the virus return.

December 6, 2013

The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a sexual deformity that affects men.

December 6, 2013

The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

FOSTER CITY, Calif. — The Food and Drug Administration has approved a new drug for hepatitis C made by Gilead Sciences, the drug maker said Friday.

December 6, 2013

Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

NORTH WALES, Pa. — Teva Pharmaceutical Industries' U.S. subsidiary has launched a generic drug for treating warts and skin lesions, the company said.

Teva Pharmaceuticals announced the launch and availability of imiquimod cream, a generic version of Medicis Pharmaceutical Corp.'s Aldara.

The drug is used to treat external genital and rectal warts, certain types of actinic keratosis and basal cell carcinoma. Various versions of the drug had sales of about $244 million in 2011, according to IMS Health.

 

December 5, 2013

Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.

NEW YORK — Compounding pharmacies that produce sterile drugs can register as outsourcing facilities and may be exempt from certain Food and Drug Administration approval requirements, according to a document published on the FDA's website.

December 5, 2013

Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

December 5, 2013

Four drug industry trade groups are suing the board of health in King County, Wash., over a local health ordinance that they say shifts the burden of sustainable disposal of unwanted drugs onto drug companies, according to published reports.

NEW YORK — Four drug industry trade groups are suing the board of health in King County, Wash., over a local health ordinance that they say shifts the burden of sustainable disposal of unwanted drugs onto drug companies, according to published reports.

December 4, 2013

The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.

PETALUMA, Calif. — The Food and Drug Administration has approved a new topical drug for treating scars made by Oculus Innovative Sciences, the drug maker said Wednesday.

The FDA has approved Microcyn scar-management hydrogel, used to treat scars resulting from burns, surgery and trauma wounds. Oculus and a partnering company, Quinnova Pharmaceuticals, intend to start selling the drug in the first half of next year.